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Abstract
Background: To evaluate the effect of Low Level Laser (LLL) application at the points of greatest pain in patients
with chronic masticatory muscle pain.
Methods: A total number of 30 (21 women, 9 men, with a mean age of 39.2) were selected after the diagnosis of
MPDS according to the Research Diagnostic Criteria for Temporomandibular Disorder (RDC/TMD). The patients were
randomly divided into three groups; laser group I (n = 10); patients received the LLL at the point of greatest pain, laser
group II (n = 10); patients received LLL at pre-established points in the effected muscles and placebo group (n = 10).
LLL and placebo were applied three times per week, for a total of 12 sessions. Mandibular mobility was examined,
masticator muscles tenderness were assessed and PPT values were obtained. Subjective pain levels were evaluated
using VAS. The measurements performed before the treatment and after the completion of the therapy. Descriptive
statistics (mean, standard deviation, and frequency) Student’s t-test, Mann–Whitney U-test and paired-sample t-tests
were used for analysis.
Results: In both laser groups, there was a statically significant reduction in PPT values of the muscles, number of muscles
without any pain on palpation increased significantly, mandibular movements’ ranges were improved. Laser
group I demonstrated statistically better results than the Laser group II in all of the measured values. Plasebo
group did not show any statistically difference in any of the measured values.
Conclusions: LLLT can be accepted as an alternative treatment modality in the management of masticatory
muscle pain and direct irradiation seems to effect better.
Trial registration: Current Controlled Trials ISRCTN31085, Date of registration 28/08/20145.
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Background
Temporomandibular disorders (TMDs) are probably the
most common cause of pain of non-dental origin in the
maxillofacial area [1]. The category of TMDs embraces a
number of clinical problems related to masticator muscles,
temporomandibular joint (TMJ) and associated structures,
or both [2]. Such disorders are characterised by pain, joint
sounds, and restricted mandibular movement. The inci-
dence of TMD ranges from 40 to 75 % in general
populations [3] and approximately 65 % of affected patients
experience associated pain [4]. This great number of
patients is treated using different modalities, depending on
the aetiology of signs and symptoms. Conservative, rather
than aggressive and irreversible, treatment is preferred to
relieve symptoms, diminish pain, and re-establish function
[5, 6]. As the aetiology of TMD is multifactorial, available
treatments are extensive and diverse, including the use of
occlusal splints, low-level laser therapy (LLLT), and trans-
cutaneous electrical nerve stimulation, among many others.
Given that better therapeutic results (i.e. pain relief) are
obtained with the combined use of modalities, several
recent studies have examined the use of LLLT to reduce
TMD pain and promote biostimulation effects [7–9].
LLLT, also known as ‘soft laser therapy’, has been investi-
gated and used in the treatment of musculoskeletal pain
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syndromes for more than 3 decades. Numerous studies
have demonstrated that LLLT effectively relieves pain and
helps to re-establish normal function in patients with
TMD [7–10]. Interest in this method is probably attribut-
able to its ease of use and low cost, although it is time
consuming. LLLT has been found to have analgesic, myor-
elaxant, tissue healing, and biostimulation effects [7–9].
The mechanisms of LLLT essentially rely on particular
visible red and infrared light waves in photoreceptors
within sub-cellular components, particularly the respira-
tory chain within mitochondrial membranes [11, 12]. This
light absorption causes activation of the respiratory chain
and oxidation of the nicotinamide adenine dinucleotide
hydrogen pool, which leads to a complex metabolic
process culminating in the stimulation of normal cell
function of the cell.
The body of literature on LLLT is large, but the results
of randomised and non-randomised clinical studies
(including those with double-blind designs) are contro-
versial. The protocols used in clinical studies have
varied in terms of power intensity and location of laser
application. Although a 632.8-nm neon-helium laser
[13]. and 660-nm [14], 780-nm [14, 15], 810-nm [16],
904-nm [17], and 830–904-nm [10] soft lasers have
been used and reported to be effective, the most
common wavelength in therapeutic use is probably
810–830 nm [18–21]. No consensus has been reached
on the choice of laser application sites for the treat-
ment of muscle pain. Some studies have employed
laser application only at pre-established points in the
affected muscles [13, 22] or acupuncture points [23],
whereas few studies [10, 24, 25] have targeted the point of
greatest pain. Evidence for the best laser application site
for the treatment of TMD of muscular origin is insuffi-
cient. Thus, the aim of this study was to investigate the
efficacy of LLLT application at different sites in the treat-
ment of TMD of muscular origin. We expected that direct
application of LLLT at the point of greatest pain would
reduce muscle pain to a greater degree than would appli-
cation at pre-established points and placebo.
Methods
This study was performed at the Department of Prostho-
dontics, School of Dentistry, University of Istanbul, Turkey.
Patients with orofacial pain who reported to the school’s
primary TMD referral centre were selected over a
period of approximately 13 months (September 2010
- October 2011). Sample selection was based on standar-
dised clinical examination using the following inclusion
criteria: 1) diagnosis of myofascial pain according to the
Research Diagnostic Criteria for Temporomandibular
Disorder (RDC/TMD) [26], 2) age 18–60 years, and 3)
natural posterior occlusion. Exclusion criteria were: 1)
disc displacement with reduction or without reduction
with or without limited opening, arthralgia, arthritis, or
arthrosis; 2) general inflammatory connective tissue dis-
ease (e.g. rheumatoid arthritis); 3) psychiatric disorder; 4)
tumour; 5) hearth disease or pacemaker; 7) pregnancy; 8)
symptoms that could be referred to other orofacial region
diseases (e.g. toothache, neuralgia, migraine); 9) treatment
or medication use for headache or bruxism in the last
2 years; and 10) local skin infection over the masseter
muscle. The Ethics Committee of the Istanbul University
Faculty of Medicine approved the study protocol. All
participants received a full explanation of the study and
provided written informed consent.
Study protocol
This study was a double-blind randomised clinical trial
(RCT). Participants were divided randomly into 3 age-
and sex-matched groups: laser group I (LGI), laser
group II (LGII) and the placebo group (PG). The ran-
domizations of the patients were done with the help of
a computer program. Patients were unaware of their
group assignments. All participants underwent three
treatment sessions per week for 1 month (total, 12
sessions). An experienced prosthodontist who was
blinded to the applied treatment evaluated the patients
twice: 30 min before the first laser application session
and 30 min after the last laser application session.
Evaluation consisted of 1) functional examination, 2)
pressure pain threshold (PPT) measurement, and 3)
subjective pain intensity measurement.
One week before the study began and during the
course of the study, patients were asked not to take any
analgesic or receive pain treatment. At the end of the
study, patients in the PG received suitable treatment,
such as an occlusal appliance or physical therapy.
Laser exposure
A continuous low-intensity semiconductor (Doris Diode
Laser, CTL 1106 MX; Warsaw, Poland) was used for laser
exposure. This device generates continuous radiation with
regulated power. The single-probe laser device applies a
laser diode generating infrared radiation of 820 nm wave-
length. The beam diameter of the device is 6 mm and the
probe has an angle of 45°. The energy intensity given to
each muscle point was adjusted to 3 J/cm2 by applying
300 mW output power for 10 s.
In all groups, the laser was applied at a 2-mm distance.
In LGI, LLLT was applied precisely and continuously to the
greatest points of pain in the related muscle (masseter and/
or temporalis). In LGII, LLLT was applied in the same
manner to three predetermined points on the masseter
muscle (superior [MS], middle [MM], and inferior [MI]
points) and three points on the temporalis muscle (anterior
[TA], middle, and posterior points). In the PG, the laser
device was switched on, but not programmed.
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Functional examination
Functional examination was based on Kurkcu’s official
Turkish translation of the RDC/TMD [26]. The same
prosthodontist examined all patients after calibration
using the RDC/TMD as the gold standard.
Masticatory muscle tenderness was assessed bilaterally
by palpation. Mobility of the mandible on opening, lateral
excursions, and protrusion was measured with a plastic
millimetre-scale ruler. Alterations in the opening pathway
were also evaluated. Patients were asked to report any
pain during muscle palpation and mandibular movements,
and this information was recorded using a verbal scale: 0,
no pain; 1, mild pain; 2, moderate pain; and 3, severe pain.
Pressure pain threshold measurement
After calibration, an experienced prosthodontist used a
dial algometer (Pain Test™ Model FPK; Wagner Instru-
ments, Greenwich, CT, USA) to measure PPTs (kg/cm2)
on the masticatory muscles. Compressions were per-
formed using a 1-cm2 rubber tip. After performing a few
test measurements on each participant’s lower arm, PPT
values were obtained before and after treatment by
applying pressure to the bilateral MS, MM, MI, and TA
points. Patients were instructed to state immediately
when the feeling of pressure became painful, at which
time the pressure was stopped. Measurements were sep-
arated by 30-s rest periods.
Pain intensity measurement
The participants were asked to evaluate their overall
pain. Their subjective pain levels (mm) were evaluated
using a 100-mm visual analogue scale (VAS) before and
after treatment.
Statistical analysis
Under the assumption of a difference of one standard
deviation in the primary endpoint among groups, an alpha
level of 5 %, and a power goal of 80 %, 10 patients per
group were determined to be necessary. For all statistical
tests, NCSS 2007 and PASS 2008 Statistical & Power Ana-
lysis Software (NCSS, Kaysville, Utah, USA) were used.
Descriptive statistics (mean, standard deviation, and
frequency) were calculated for all variables. Quantitative
data were compared using Student’s t-test for normally
distributed parameters and the Mann–Whitney U-test for
non-normally distributed parameters. Within-group com-
parison of normally distributed parameters was performed
using paired-sample t-tests. The results were analysed
using 95 % confidence intervals, with a significance level
of p < 0.05.
Results
Sixty-two of 814 examined patients with TMD of mus-
cular origin fulfilled the inclusion criteria, and 33 of
these patients agreed to participate in the study. Three
enrolled patients did not attend appointments regularly
and were excluded from the study. The study sample
thus comprised 30 patients with TMD of muscular
origin (21 women, 9 men; mean age, 39.2 ± 2.8 years)
allocated to the three study groups (n = 10 per group).
We identified no significant difference in age, sex, or
pain duration among groups. Participants’ demographic
characteristics are shown in Table 1.
Participants in all groups reported the most severe pain
in the masseter muscle. Laser exposure significantly
reduced pain on palpation and (Table 2). Pain severity also
decreased slightly in the PG (Table 2). It demonstrates the
percentage of the pain intensity of the examined muscles
before and after real laser exposure and placebo laser
application in each group. The intensity of pain was
reduced more in LGI than in LGII. PPTs of the examined
muscles increased significantly in the LLLT groups, but
not in the PG (Table 3). Although the difference between
LGI and LGII was not statistically significant, LGI demon-
strated slightly better results. Vertical movement, lateral
excursions, and protrusion also improved significantly in
the LLLT groups (Table 4). Pre- and post-treatment VAS
scores differed significantly in the LLLT groups, but not
in the PG (Table 5). No patient reported any adverse
effect related to laser application during or after the
treatment period.
Discussion
The present study demonstrated that the tested type of
LLLT, applied bilaterally, was beneficial in the treatment
of TMD of muscular origin. Patients who received LLLT
Table 1 Demographic data of the groups
LGI LGII PG p
Mean ± SD Mean ± SD Mean ± SD
Age 30,80 ± 9,81 29,33 ± 8,59 31,94 ± 12,20 a0.531
Gender
Male 3 3 3
b0.373
Female 7 7 7
Pain duration (months) 10.5 ± 1.7 9.8 ± 1.1 10.2 ± 1.9 a 0.289
aOneway ANOVA Test
bchi-square test
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showed significant improvements in the tested parame-
ters, whereas those in the PG did not. However, the
study hypothesis that direct application of a low-level
laser to the sites of most severe pain would produce
better results than laser application at predetermined
points was not supported. Direct application appeared to
be slightly superior to traditional point irradiation, but
differences were not significant.
Several previous clinical studies have investigated the
effects of LLLT on TMD of myogenic origin using objective
and subjective measures of PPTs, mandibular movements,
and muscle pain on palpation [7–9]. The documented vari-
ation in these effects can be explained by many factors,
including methodological differences among studies (e.g.
use of placebo, double-blind design, sample characteristics)
and LLLT parameters (e.g. application point, wavelength,
power output, energy intensity, exposure duration).
Furthermore, the effect of a low-level laser increases
with the depth of penetration into musculoskeletal
tissues. Wavelength and energy density play important
roles in light penetration and absorption. In the current
study, a light with 820 nm wavelength, 3 J/cm2, and
300 mW output was used because these parameters
have been reported to be effective for muscle disorders
[10]. Gallium-arsenide lasers have been reported to
penetrate to depths of 1–5 cm in soft tissue [27], which
should be adequate to achieve a therapeutic effect in
muscle disorders. The absence in the present study of a
significant benefit of direct laser application to the points
of greatest muscle pain, which we hypothesised would
more effectively target affected tissue, may be due to the
limited size of the treated muscle, which resulted in con-
siderable similarity of such targeting to the treatment of
predetermined points. In a muscle with larger area and
greater thickness, such targeted application might achieve
better results.
Pain was the chief complaint of patients in the current
study. Pain levels were evaluated subjectively (with a VAS)
at the beginning and end of the study. In clinical trials
designed to investigate the efficacy of therapies aiming to
resolve or reduce pain, the primary endpoint is reduction in
pain intensity [28]. For chronic pain, most measures of
treatment response involve patient-reported outcomes, as
patients are the most important judges of whether changes
are relevant [29–31]. The evaluation of pain is difficult
because it is not controlled in clinical research; this com-
plex procedure requires the assessment of biological, struc-
tural, functional, and emotional pain experiences. Recent
chronic pain studies have recommended the evaluation of
pain using subjectively reported primary measures [28, 29].
However, clinical assessment should also involve an object-
ive and quantitative evaluation of pain, such as PPT meas-
urement, which enhances the quality of data and enables
outcome standardisation and comparison. In the present
study, objective functional measures based on the RDC/
TMD and PPT values were recorded with the aid of an alg-
ometer to accompany patient-reported pain intensity data.
PPT values supported the VAS results.
Table 3 Comparison of PPT (kg/cm2) values. Each line demonstrates the statistical analysis of a muscle before and after laser exposure
Laser Group I Laser Group II Placebo Group
M (kg/cm2) SD p M (kg/cm2) SD p M (kg/cm2) SD p
TA 30.55 4.98 0.017532* 31.55 4.82 0.027532* 34.32 5.67 0.27757 **
TM 33.42 5.37 0.00922 * 35.42 5.71 0.02022 * 36.97 4.36 0.52936 **
TP 32.12 5.71 0.00574 * 36.50 5.67 0.00274 * 38.07 4.46 0.26742 **
MS 22.75 5.52 0.00756 * 23.11 5.86 0.00956 * 25.50 6.00 0.55225 **
MM 20.87 4.87 0.00203 * 19.45 4.44 0.00303 * 23.60 4.72 0.94166 **
MI 23.22 5.11 0.00032 * 19.22 5.05 0.00062 * 26.10 5.52 0.70732 **
SCM 21.77 5.80 0.00031 * 21.50 4.48 0.00061 * 24.75 5.95 0.95113 **
Student t test was used
M mean, SD Standard deviation, 95 % confidence interval, * p < 0.05 statistically significant, ** p ≥ .05 statistically non-significant
TA temporalis anterior, TM temporalis middle, TP temporalis posterior, MS masseter superior, MM masseter middle, MI masseter inferior, SCM sternocleidomasteideous
Table 2 The results of muscle palpations
LGI LGII LGII
n (%) n (%) n (%)
TA Before treatment 40 Before treatment 40 Before treatment 50
After treatment 30 After treatment 30 After treatment 50
TM Before treatment 40 Before treatment 40 Before treatment 40
After treatment 30 After treatment 20 After treatment 30
TP Before treatment 10 Before treatment 40 Before treatment 20
After treatment 10 After treatment 40 After treatment 20
MS Before treatment 80 Before treatment 80 Before treatment 70
After treatment 40 After treatment 60 After treatment 70
MM Before treatment 90 Before treatment 80 Before treatment 90
After treatment 60 After treatment 50 After treatment 80
MI Before treatment 80 Before treatment 90 Before treatment 80
After treatment 40 After treatment 50 After treatment 70
TA temporalis anterior, TM temporalis middle, TP temporalis posterior, MS masseter
superior, MM masseter middle, MImasseter inferior
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In 2004, the World Association of Laser Therapy
approved an agreement on the design of clinical studies
employing LLLT; the use of a PG was established as a
mandatory component [http://waltza.co.za/wpcontent/
uploads/2012/08/walt_standard_for_conduct_of_rando-
mized_controlled_trials.pdf]. Accordingly, an age- and
sex-matched PG was included in the present study.
The PG showed slight, but not significant, improvement
in all tested parameters. These improvements could be
explained by many factors. The most likely explanation
involves the positive reactions of patients to technologic-
ally advanced laser treatment. Furthermore, palpation,
which was a treatment component for all study subjects
(including those in the PG), can relieve pain [32].
The present study does have some limitations. The
present study examined the effect of specific dose of
LLLT on pain release and mandibular function and
found out that active laser is superior to sham applica-
tion. However the only the short-term effects were
investigated. Additional research should be conducted in
order to investigate the long-term effects of LLL in the
treatment of TMD. Furthermore only one type of laser
settings was used. Different light intensities might have
produced different or better results. In order to be able
to suggest a treatment protocol, a study population
with greater sample size, followed-up for longer period
and treated with different low-level laser parameter
should be used.
Conclusions
Within the limitations of the present clinical trial, the tested
type of LLLT (820 nm, 3 J/cm2, 300 mW output power)
showed positive effects in managing pain caused by TMD
and improving mandibular function due to its analgesic and
myorelaxant effects. The localisation of laser application (at
predetermined points vs. points of greatest pain), however,
did not affect the results of LLLT. Further double-blind,
randomised, placebo-controlled clinical research is needed
to establish whether these findings have clinical relevance.
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